- Home
- MOS vs HALO Comparison
MOS vs HALO Comparison
Compare MOS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- HALO
- Stock Information
- Founded
- MOS 1987
- HALO 1998
- Country
- MOS United States
- HALO United States
- Employees
- MOS 13765
- HALO N/A
- Industry
- MOS Agricultural Chemicals
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOS Industrials
- HALO Health Care
- Exchange
- MOS Nasdaq
- HALO Nasdaq
- Market Cap
- MOS 11.2B
- HALO 7.4B
- IPO Year
- MOS 2004
- HALO N/A
- Fundamental
- Price
- MOS $37.26
- HALO $52.80
- Analyst Decision
- MOS Buy
- HALO Buy
- Analyst Count
- MOS 12
- HALO 9
- Target Price
- MOS $34.83
- HALO $63.56
- AVG Volume (30 Days)
- MOS 6.2M
- HALO 2.9M
- Earning Date
- MOS 08-05-2025
- HALO 08-05-2025
- Dividend Yield
- MOS 2.36%
- HALO N/A
- EPS Growth
- MOS N/A
- HALO 55.40
- EPS
- MOS 1.15
- HALO 3.76
- Revenue
- MOS $11,064,300,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- MOS $17.03
- HALO $25.77
- Revenue Next Year
- MOS N/A
- HALO $18.01
- P/E Ratio
- MOS $32.28
- HALO $14.37
- Revenue Growth
- MOS N/A
- HALO 25.64
- 52 Week Low
- MOS $22.36
- HALO $42.01
- 52 Week High
- MOS $38.06
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- MOS 69.11
- HALO 50.36
- Support Level
- MOS $34.88
- HALO $51.06
- Resistance Level
- MOS $38.06
- HALO $54.25
- Average True Range (ATR)
- MOS 0.90
- HALO 1.22
- MACD
- MOS 0.07
- HALO 0.23
- Stochastic Oscillator
- MOS 90.23
- HALO 84.97
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.